FRIDAY, Might 24, 2024 (HealthDay Information) — A once-daily dose of donepezil doesn’t enhance cognitive perform amongst breast most cancers survivors uncovered to chemotherapy one to 5 years earlier, in response to a research printed on-line Might 6 within the Journal of Scientific Oncology.
Stephen R. Rapp, Ph.D., from the Wake Forest College Faculty of Drugs in Winston-Salem, North Carolina, and colleagues examined the efficacy of the cognitive enhancer donepezil for enhancing reminiscence in breast most cancers survivors who report cancer-related cognitive impairment one to 5 years after chemotherapy. Grownup feminine breast most cancers survivors uncovered to 4 or extra cycles of adjuvant chemotherapy one to 5 years earlier than enrollment had been eligible and randomly assigned to obtain 5 mg donepezil as soon as every day for six weeks titrated to 10 mg as soon as every day for 18 weeks or placebo (140 and 136 members, respectively).
The researchers discovered that the therapy teams didn’t differ by way of Hopkins Verbal Studying Check-Revised scores at 24 weeks (imply, 25.98 and 26.50 for donepezil and placebo, respectively). No statistically important variations had been seen between therapies for consideration, govt perform, verbal fluency, processing pace, or self-reported cognitive performing at 12, 24, or 36 weeks. The outcomes weren’t affected by endocrine remedy or menopausal standing.
“We discovered that the members didn’t carry out otherwise on the finish of therapy on checks of reminiscence, different cognitive capabilities, or subjective functioning than these randomly assigned to placebo,” Rapp mentioned in a press release.
A number of authors disclosed ties to the biopharmaceutical and medical expertise industries.
Summary/Full Textual content (subscription or cost could also be required)
Adblock check (Why?)